We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Pacira (PCRX) Down 4.5% Since the Last Earnings Report?
Read MoreHide Full Article
A month has gone by since the last earnings report for Pacira Pharmaceuticals, Inc. (PCRX - Free Report) . Shares have lost about 4.5% in that time frame, underperforming the market.
Will the recent negative trend continue leading up to the stock's next earnings release, or is it due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Pacira Posts Wider-than-Expected Loss in Q1, Sales Miss
Pacira reported first-quarter 2017 loss of $0.38 (including the impact of stock-based compensation), wider than the Zacks Consensus Estimate loss of $0.23 and the year-ago loss of $0.08.
Revenues also rose 5.8% year over year to $69.3 million and missed the Zacks Consensus Estimate of $71 million.
Quarter in Detail
Pacira’s top line comprises product revenues, collaborative licensing and milestone revenues, and royalty revenues. Its lead product, Exparel, generated revenues of $67.7 million, up 6.2% year over year. But DepoCyt(e) and other product revenues came in at $0.7 million, down 3.5%.
Collaborative licensing and milestone revenues were down 42.1% to $0.2 million. Royalty revenues were $0.7 million, up 5.8%.
Research and development (R&D) expenses were up 75.2% to $16.6 million, while selling, general and administrative (SG&A) expenses increased 11% to $42.1 million.
2017 Outlook
The company reiterated its guidance for 2017. Pacira projects Exparel sales in the range of $290 million to $310 million. R&D expenses are expected in the band of $50 million to $60 million. SG&A expenses are expected to be in $145–$155 million range. Also, stock-based compensation is forecast to be in the range of $30 -$35 million.
How Have Estimates Been Moving Since Then?
Analysts were quiet during the last one month period as none of them issued any earnings estimate revisions.
At this time, Pacira's stock has a poor Growth score of 'F', however its momentum is doing a lot better with a 'B'. The stock was allocated a grade of 'D' on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of 'F'. If you aren't focused on one strategy, this score is the one you should be interested in.
Zacks' style scores indicate that the company's stock is solely suitable for momentum investors.
Outlook
The stock has a Zacks Rank #4 (Sell). We are expecting a below average return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Is Pacira (PCRX) Down 4.5% Since the Last Earnings Report?
A month has gone by since the last earnings report for Pacira Pharmaceuticals, Inc. (PCRX - Free Report) . Shares have lost about 4.5% in that time frame, underperforming the market.
Will the recent negative trend continue leading up to the stock's next earnings release, or is it due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Pacira Posts Wider-than-Expected Loss in Q1, Sales Miss
Pacira reported first-quarter 2017 loss of $0.38 (including the impact of stock-based compensation), wider than the Zacks Consensus Estimate loss of $0.23 and the year-ago loss of $0.08.
Revenues also rose 5.8% year over year to $69.3 million and missed the Zacks Consensus Estimate of $71 million.
Quarter in Detail
Pacira’s top line comprises product revenues, collaborative licensing and milestone revenues, and royalty revenues. Its lead product, Exparel, generated revenues of $67.7 million, up 6.2% year over year. But DepoCyt(e) and other product revenues came in at $0.7 million, down 3.5%.
Collaborative licensing and milestone revenues were down 42.1% to $0.2 million. Royalty revenues were $0.7 million, up 5.8%.
Research and development (R&D) expenses were up 75.2% to $16.6 million, while selling, general and administrative (SG&A) expenses increased 11% to $42.1 million.
2017 Outlook
The company reiterated its guidance for 2017. Pacira projects Exparel sales in the range of $290 million to $310 million. R&D expenses are expected in the band of $50 million to $60 million. SG&A expenses are expected to be in $145–$155 million range. Also, stock-based compensation is forecast to be in the range of $30 -$35 million.
How Have Estimates Been Moving Since Then?
Analysts were quiet during the last one month period as none of them issued any earnings estimate revisions.
Pacira Pharmaceuticals, Inc. Price and Consensus
Pacira Pharmaceuticals, Inc. Price and Consensus | Pacira Pharmaceuticals, Inc. Quote
VGM Scores
At this time, Pacira's stock has a poor Growth score of 'F', however its momentum is doing a lot better with a 'B'. The stock was allocated a grade of 'D' on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of 'F'. If you aren't focused on one strategy, this score is the one you should be interested in.
Zacks' style scores indicate that the company's stock is solely suitable for momentum investors.
Outlook
The stock has a Zacks Rank #4 (Sell). We are expecting a below average return from the stock in the next few months.